ARTICLE | Company News
Eisai obtains license from Elan
October 11, 2000 7:00 AM UTC
ELN granted Eisai (Tokyo, Japan) an exclusive license to develop and market in Japan its NeuroBloc botulinum toxin type B to treat cervical dystonia. ELN will manufacture and supply the product. ...